April 30, 2020 / 7:34 AM / a month ago

BRIEF-Verona Pharma Says Cash Position Of 20.8 Mln STG At March-end

April 30 (Reuters) - Verona Pharma PLC:

* VERONA PHARMA PLC - FDA HAS ADVISED THAT IT WILL PROVIDE A WRITTEN RESPONSE TO COMPANY ON ITS END-OF-PHASE 2 PACKAGE, RATHER THAN HOLDING A MEETING

* VERONA PHARMA PLC - EXPECTING TO RECEIVE FDA RESPONSE DURING Q2 OF 2020

* VERONA PHARMA PLC - NET CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AT MARCH 31, 2020 AMOUNTED TO £20.8 MILLION (DECEMBER 31, 2019: £30.8 MILLION)

* VERONA PHARMA PLC - QTRLY OPERATING LOSS OF £11.2 MILLION (THREE MONTHS ENDED MARCH 31, 2019: £7.8 MILLION)

* VERONA PHARMA - INITIATION OF PHASE 3 FOR ENSIFENTRINE FOR TREATMENT OF COPD ANTICIPATED LATER THIS YEAR, SUBJECT TO SECURING ADDITIONAL FUNDING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below